Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | integrin, alpha V | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | integrin alpha ps | integrin, alpha V | 1002 aa | 908 aa | 22.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | glutaminase DH11.1 | 0.0278 | 0.9761 | 1 |
Mycobacterium ulcerans | glutaminase | 0.0278 | 0.9761 | 1 |
Echinococcus multilocularis | integrin alpha ps | 0.004 | 0.0773 | 0.1677 |
Loa Loa (eye worm) | hepatopoietin HPO2 | 0.0035 | 0.0594 | 0.0594 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0019 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0102 | 0.3116 | 0.3116 |
Echinococcus multilocularis | integrin alpha ps | 0.0083 | 0.2397 | 0.5199 |
Echinococcus granulosus | integrin alpha 3 | 0.0142 | 0.461 | 1 |
Plasmodium falciparum | FAD-linked sulfhydryl oxidase ERV1, putative | 0.0035 | 0.0594 | 1 |
Trypanosoma cruzi | Present in the outer mitochondrial membrane proteome 4 | 0.0035 | 0.0594 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.014 | 0.454 | 0.454 |
Schistosoma mansoni | integrin alpha | 0.0185 | 0.6234 | 0.6386 |
Trypanosoma cruzi | Present in the outer mitochondrial membrane proteome 4 | 0.0035 | 0.0594 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0019 | 0 | 0.5 |
Toxoplasma gondii | Erv1 / Alr family protein | 0.0035 | 0.0594 | 1 |
Echinococcus granulosus | FAD linked sulfhydryl oxidase ALR | 0.0035 | 0.0594 | 0.1289 |
Echinococcus multilocularis | integrin alpha 3 | 0.0142 | 0.461 | 1 |
Schistosoma mansoni | integrin alpha-ps | 0.0043 | 0.0902 | 0.0924 |
Brugia malayi | Integrin alpha cytoplasmic region family protein | 0.014 | 0.454 | 0.4651 |
Trichomonas vaginalis | glutaminase, putative | 0.0278 | 0.9761 | 1 |
Loa Loa (eye worm) | glutaminase 2 | 0.0278 | 0.9761 | 0.9761 |
Echinococcus granulosus | integrin alpha ps | 0.004 | 0.0773 | 0.1677 |
Trypanosoma brucei | ERV/ALR sulfhydryl oxidase domain-containing protein | 0.0035 | 0.0594 | 1 |
Trypanosoma cruzi | ERV/ALR sulfhydryl oxidase domain-containing protein | 0.0035 | 0.0594 | 1 |
Brugia malayi | Augmenter of liver regeneration | 0.0035 | 0.0594 | 0.0609 |
Loa Loa (eye worm) | glutaminase | 0.0278 | 0.9761 | 0.9761 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0019 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0019 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0145 | 0.4739 | 0.4739 |
Echinococcus multilocularis | integrin alpha ps | 0.0083 | 0.2397 | 0.5199 |
Echinococcus multilocularis | FAD linked sulfhydryl oxidase ALR | 0.0035 | 0.0594 | 0.1289 |
Loa Loa (eye worm) | hypothetical protein | 0.0043 | 0.0902 | 0.0902 |
Echinococcus granulosus | integrin alpha ps | 0.0083 | 0.2397 | 0.5199 |
Schistosoma mansoni | hypothetical protein | 0.004 | 0.0773 | 0.0792 |
Toxoplasma gondii | Erv1 / Alr family protein | 0.0035 | 0.0594 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.0773 | 0.0773 |
Brugia malayi | Integrin alpha pat-2 precursor | 0.0185 | 0.6234 | 0.6386 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0019 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0035 | 0.0594 | 1 |
Plasmodium vivax | FAD-linked sulfhydryl oxidase ERV1, putative | 0.0035 | 0.0594 | 1 |
Schistosoma mansoni | glutaminase | 0.0278 | 0.9761 | 1 |
Schistosoma mansoni | integrin alpha-ps | 0.0083 | 0.2397 | 0.2455 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 11 nM | Inhibition of fibrinogen binding to alphavbeta3 integrin | ChEMBL. | 19574045 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.